Page 377 - Williams Hematology ( PDFDrive )

352 Part VI: The Erythrocyte

313. Marcus R, Imrie K, Belch A, et al: CVP chemotherapy plus rituximab compared with CVP 331. Wierda WG, Kipps TJ, Mayer J, et al: Ofatumumab as single-agent CD20 immuno-
as first-line treatment for advanced follicular lymphoma. Blood 105:1417–1423, 2005. therapy in fludarabine-refractory chronic lymphocytic leukemia. J Clin Oncol 28:
314. Habermann TM, Weller EA, Morrison VA, et al: Rituximab-CHOP versus CHOP alone 1749–1755, 2010.
or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J 332. Patz M, Isaeva P, Forcob N, et al: Comparison of the in vitro effects of the anti-CD20
Clin Oncol 24:3121–3127, 2006. antibodies rituximab and GA101 on chronic lymphocytic leukaemia cells. Br J Haema-
315. Davis TA, Grillo-López AJ, White CA, et al: Rituximab anti-CD20 monoclonal anti- tol 152:295–306, 2011.
body therapy in non-Hodgkin’s lymphoma: Safety and efficacy of re-treatment. J Clin 333. Goede V, Fischer K, Busch R, et al: Obinutuzumab plus chlorambucil in patients with
Oncol 18:3135–3143, 2000. CLL and coexisting conditions. N Engl J Med 370:1101–1110, 2014.
316. Salles G, Seymour JF, Offner F, et al: Rituximab maintenance for 2 years in patients with 334. Kumar S, Kimlinger TK, Lust JA, et al: Expression of CD52 on plasma cells in plasma
high tumour burden follicular lymphoma responding to rituximab plus chemotherapy cell proliferative disorders. Blood 102:1075–1077, 2003.
(PRIMA): A phase 3, randomised controlled trial. Lancet 377:42–51, 2011. 335. Villamor N, Montserrat E, Colomer D: Mechanism of action and resistance to mono-
317. van Oers MH, Van Glabbeke M, Giurgea L, et al: Rituximab maintenance treatment clonal antibody therapy. Semin Oncol 30:424–433, 2003.
of relapsed/resistant follicular non-Hodgkin’s lymphoma: Long-term outcome of the 336. Hillmen P, Skotnicki AB, Robak T, et al: Alemtuzumab compared with chlorambucil
EORTC 20981 phase III randomized intergroup study. J Clin Oncol 28:2853–2858, 2010. as first-line therapy for chronic lymphocytic leukemia. J Clin Oncol 25:5616–5623,
318. Hainsworth JD, Litchy S, Burris HA 3rd, et al: Rituximab as first-line and mainte- 2007.
nance therapy for patients with indolent non-Hodgkin’s lymphoma. J Clin Oncol 20: 337. Keating MJ, Flinn I, Jain V, et al: Therapeutic role of alemtuzumab (Campath-1H)
4261–4267, 2002. in patients who have failed fludarabine: Results of a large international study. Blood
319. Maloney DG, Grillo-López AJ, Bodkin DJ, et al: IDEC-C2B8: Results of a phase I 99:3554–3561, 2002.
multiple-dose trial in patients with relapsed non-Hodgkin’s lymphoma. J Clin Oncol 338. Gallamini A, Zaja F, Patti C, et al: Alemtuzumab (Campath-1H) and CHOP che-
15:3266–3274, 1997. motherapy as first-line treatment of peripheral T-cell lymphoma: Results of a GITIL
320. Cartron G, Watier H, Golay J, Solal-Celigny P: From the bench to the bedside: Ways to (Gruppo Italiano Terapie Innovative nei Linfomi) prospective multicenter trial. Blood
improve rituximab efficacy. Blood 104:2635–2642, 2004. 110:2316–2323, 2007.
321. Berinstein NL, Grillo-López AJ, White CA, et al: Association of serum Rituximab 339. Varga C, Laubach J, Hideshima T, et al: Novel targeted agents in the treatment of multi-
(IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent ple myeloma. Hematol Oncol Clin North Am 28:903–925, 2014.
low-grade or follicular non-Hodgkin’s lymphoma. Ann Oncol 9:995–1001, 1998. 340. Richardson PG, Lonial S, Jakubowiak AJ, et al: Monoclonal antibodies in the treatment
322. Cartron G, Dacheux L, Salles G, et al: Therapeutic activity of humanized anti-CD20 of multiple myeloma. Br J Haematol 154:745–754, 2011.
monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. 341. Lonial S, Kaufman J, Laubach J, Richardson P: Elotuzumab: A novel anti-CS1 mono-
Blood 99:754–758, 2002. clonal antibody for the treatment of multiple myeloma. Expert Opin Biol Ther 13:
323. Farag SS, Flinn IW, Modali R, et al: Fc gamma RIIIa and Fc gamma RIIa polymor- 1731–1740, 2013.
phisms do not predict response to rituximab in B-cell chronic lymphocytic leukemia. 342. Laubach JP, Tai YT, Richardson PG, Anderson KC: Daratumumab granted break-
Blood 103:1472–1474, 2004. through drug status. Expert Opin Investig Drugs 23:445–452, 2014.
324. Lowndes S, Darby A, Mead G, Lister A: Stevens-Johnson syndrome after treatment with 343. Dang NH, Pro B, Hagemeister FB, et al: Phase II trial of denileukin diftitox for relapsed/
rituximab. Ann Oncol 13:1948–1950, 2002. refractory T-cell non-Hodgkin lymphoma. Br J Haematol 136:439–447, 2007.
325. Kranick SM, Mowry EM, Rosenfeld MR: Progressive multifocal leukoencephalopathy 344. Larson RA, Sievers EL, Stadtmauer EA, et al: Final report of the efficacy and safety
after rituximab in a case of non-Hodgkin lymphoma. Neurology 69:704–706, 2007. of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid
326. Cattaneo C, Spedini P, Casari S, et al: Delayed-onset peripheral blood cytopenia after leukemia in first recurrence. Cancer 104:1442–1452, 2005.
rituximab: Frequency and risk factor assessment in a consecutive series of 77 treat- 345. Francisco JA, Cerveny CG, Meyer DL, et al: CAC10-vcMMAE, an anti-CD30-
ments. Leuk Lymphoma 47:1013–1017, 2006. monomethyl auristatin E conjugate with potent and selective antitumor activity. Blood
327. Cabanillas F, Liboy I, Pavia O, Rivera E: High incidence of non-neutropenic infections 102:1458–1465, 2003.
induced by rituximab plus fludarabine and associated with hypogammaglobulinemia: A 346. Younes A, Gopal AK, Smith SE, et al: Results of a pivotal phase II study of brentuxi-
frequently unrecognized and easily treatable complication. Ann Oncol 17:1424–1427, 2006. mab vedotin for patients with relapsed or refractory Hodgkin’s lymphoma. J Clin Oncol
328. Teeling JL, French RR, Cragg MS, et al: Characterization of new human CD20 mono- 30:2183–2189, 2012.
clonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas. Blood 347. Horning SJ, Younes A, Jain V, et al: Efficacy and safety of tositumomab and iodine-131
104:1793–1800, 2004. tositumomab (Bexxar) in B-cell lymphoma, progressive after rituximab. J Clin Oncol
329. Teeling JL, Mackus WJ, Wiegman LJ, et al: The biological activity of human CD20 mono- 23:712–719, 2005.
clonal antibodies is linked to unique epitopes on CD20. J Immunol 177:362–371, 2006. 348. Horning SJ, Weller E, Kim K, et al: Chemotherapy with or without radiotherapy in lim-
330. Hagenbeek A, Gadeberg O, Johnson P, et al: First clinical use of ofatumumab, a novel ited-stage diffuse aggressive non-Hodgkin’s lymphoma: Eastern Cooperative Oncology
fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lym- Group study 1484. J Clin Oncol 22:3032–3038, 2004.
phoma: Results of a phase 1/2 trial. Blood 111:5486–5495, 2008.

Kaushansky_chapter 22_p0313-0352.indd 352 9/18/15 10:26 PM